ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
bc-mhcp-pharmprogpolicynotifctn-eff-9-1-24.pdf
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 1181 - 1190 လၢ 5055 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P57-24 MagellanRx Management, a Prime Therapeutics Company (UM) Program: Medical Drug Updates
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 03, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP68-24 MHCP Pharmacy Benefit Exclusion for Kisunla™, PiaSky®, and Tecelra®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 28, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP67-24 Commercial Pharmacy Benefit Exclusion for edaravone, Kisunla™, PiaSky®, and Tecelra®
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 28, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP65-24 PCA Agency Requirements
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 28, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP66-24 Reminder: Patient Complaint Policy and Process Requirements
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 28, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP62-24 Commercial Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective October 1, 2024
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 14, 2024
တၢ်ဃ့က့ၤအဘူးအလဲ ဒီးတၢ်ပတံသကွံာ်ကညးတၢ်တဖၣ်
တၢ်န့ၢ်ဘျုးဒီးတၢ်ဟ့ၣ်အဘူးအလဲ
Blue Plus Member Authorization form
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP64-24 MHCP Pharmacy Benefit Exclusion for Rytelo™
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 14, 2024
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP63-24 MHCP Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective September 1, 2024
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါအီကူာ် 14, 2024